Under a new research and development deal between Allergan and Editas Medicine, Inc., Allergan will get exclusive access and the option to license up to five of Editas’ experimental gene-editing-based eye treatments.  Editas’ gene-editing technology is CRISPR, which is expected to revolutionize the treatment of genetic diseases.  CRISPR “works as a type of molecular scissors that can trim away unwanted pieces of genetic material, and replace them with new ones.” (Reuters)